Published in final edited form as:

Biomol Concepts. 2012 December 1; 3(6): 581–591. doi:10.1515/bmc-2012-0025.

Milk lipid secretion: recent biomolecular aspects

James L. McManaman

Division of Reproductive Sciences, Department of Obstetrics and Gynecology, Graduate Programs in Cell Biology, Stem Cells and Development, Molecular Biology and Reproductive Sciences, University of Colorado, School of Medicine, Aurora, CO 80045, USA

James L. McManaman: jim.mcmanaman@ucdenver.edu

Abstract

Neonates of most species depend on milk lipids for calories, fat-soluble vitamins, and bioactive lipid components for growth and development during the postnatal period. To meet neonatal nutrition and development needs, the mammary gland has evolved efficient mechanisms for synthesizing and secreting large quantities of lipid during lactation. Although the biochemical steps involved in milk lipid synthesis are understood, the identities of the genes mediating these steps and the molecular physiology of milk lipid production and secretion have only recently begun to be understood in detail through advances in mouse genetics, gene expression analysis, protein structural properties, and the cell biology of lipid metabolism. This review discusses emerging data about the molecular, cellular, and structural determinants of milk lipid synthesis and secretion within the context of physiological functions.

Keywords

cellular mechanisms; endoplasmic reticulum; milk lipid; molecular model; secretion

Introduction

Milk lipids are a major source of the calories needed for neonatal growth in most species (1), and provide a mechanism for delivery of fat-soluble vitamins and essential fatty acids to developing infants. Observations that the lipid content of milk can vary from around 50% (w/v) in fur seals and other aquatic mammals to slightly more than 1% in donkeys (www.havemilk.com) suggest that the processes regulating milk lipid production have been conditioned by evolution to meet species-specific nutritional needs of offspring. In species where it has been studied, it is estimated that milk lipid production makes significant demands on maternal metabolism, requiring adaptations in nutrient intake, trafficking, and utilization (2). In humans and rodents, it is thought that during lactation the mammary gland is one of the most active lipid-synthesizing and lipid-secreting organs in the body (2–4). To meet milk lipid production demands, the mammary gland must be able to efficiently synthesize, transport, and secrete triglycerides (TAG). Because these processes are induced during pregnancy as the mammary gland develops into a secretory organ (5), and they represent robust functions of the mammary gland during lactation, the mammary gland has long represented an important model for investigating the biochemistry, cell biology, and physiology of lipid metabolism. Although much of the general framework of milk lipid synthesis and secretion has been known for years (6), the cellular and molecular mechanisms mediating these functions have only recently begun to be uncovered. This review focuses on advances in understanding the molecular and cellular processes governing synthesis and secretion of milk lipids, and conceptual insights gained from these studies.

Mechanisms of milk lipid production

Milk lipids are derived by secretion of cytoplasmic lipid droplets (CLD). These organelle-like structures, which are found in most cell types, function in the regulation of neutral lipid storage, hydrolysis, and trafficking, and there is increasing evidence that they play important roles in controlling cellular lipid homeostasis (7). Many of the basic structural features of CLD are similar to those of serum lipoproteins. They are composed of a neutral lipid core, which in mammary epithelial cells is >95% triacylglycerol. Like lipoprotein particles, their neutral lipid core is surrounded by a monolayer of phospholipids, and coated by specific classes of proteins that serve structural and functional roles (8).

Extensive evidence from the study of the mammary gland and other tissues indicate that CLD originate from the endoplasmic reticulum (ER), by processes that as yet are not fully understood (6, 9–12). The prevailing view is that CLD originate by budding of neutral lipids that accumulate as lens-type structures between ER membrane leaflets (10). Although this mechanism appears to account for the known structural organization of CLD, neither lens-like structures nor budding CLD have been unequivocally observed (11), even in highly lipogenic organs, such as the mammary gland (unpublished observations). An alternative view is that neutral lipids are synthesized in specialized ER-cytoplasmic domains that form ‘egg cup-like’ structures (11). Three-dimensional freeze-fracture studies documenting the presence of lipid droplets partially enveloped by ER membranes (11) support this model; however, the model does not entirely account for the known structural features of CLD. A variation of the ‘egg cup’ model suggests that CLD originate from interactions of ER loops containing neutral lipid synthesis domains (12). Like the ‘egg cup’ model, this model can account for some but not all of the structural features of CLD.

Despite these limitations, neutral lipids are known to be synthesized by ER enzymes (Figure 1) (13–15), and ultra-structural and proteomic studies have demonstrated that CLD directly contact ER membranes (16, 17). Moreover, newly synthesized TAG have been shown to be rapidly incorporated into ER-associated CLD in lactating mammary tissue (9) and *de novo* generation of CLD has been demonstrated in ER-microsome fractions isolated from lactating mammary glands (18).

Significantly, there is marked ER expansion during mammary gland differentiation (19–21), and in species in which it has been studied, the ER accounts for approximately 25% of the total volume of mammary epithelial cells in lactating animals (21). Thus, CLD production by ER processes may represent a regulatory step in the overall rate by which lipids are transferred into milk. Loss- and gain-of-function studies have identified TAG synthesis and stabilization, as well as *de novo* fatty acid synthesis, as critical physiological regulators of CLD and milk lipid production.

TAG synthesis

The TAG core of CLD is synthesized by sequential fatty acid esterification of glycerol-3-phosphate (22) or sn-2-monoacylglycerol (23), by enzymes located in the ER (Figure 1). The final step, esterification of diacylglycerol (DAG) to form TAG, is catalyzed by diacylglycerol *O*-acyltransferase (DGAT). Two genetically different DGAT isoforms (DGAT1, DGAT2), with different physiological functions, are present in mammalian tissues (24, 25). DGAT1 appears to be specifically responsible for TAG synthesis by mammary epithelial cells (Figure 1). DGAT1-null mice are viable and possess significant amounts of white adipose tissue; however, they have altered metabolic properties, defects in hair growth, and fail to lactate (26). Histological and electron microscopic analyses showed that the development of their mammary glands was impaired, and that CLD were absent from their mammary epithelial cells (26, 27). Through transplantation experiments, it was shown

that loss of DGAT1 in the stromal compartment of the mammary gland was responsible for glandular development defects. DGAT1 loss in mammary epithelial cells, however, did not appear to affect or impair mammary gland development but did result in failure to form CLD in mammary epithelial cells and undergo functional differentiation (27). Evidence in cattle showing that catalytic activity enhancing mutations in DGAT1 are associated with increased milk lipid content further implicates TAG synthesis as a rate-limiting step in CLD and milk lipid production (28).

Synthesis of DAG in mammary epithelial cells occurs by the glycerol-3-phosphate pathway. Members of the glycerol-3-phosphate acyltransferase (GPAT) family catalyze the first acylation step in this process, the formation of lysophosphatidic acid (LPA) from glycerol-3-phosphate (Figure 1) (29). Mammals express four GPAT isoforms (29). However, only GPAT4 appears to play a physiologically significant role in catalyzing glycerol-3-phosphate acylation to form milk lipids. Transcript levels of this isoform increase in mammary glands of mice and cattle in response to lactation (30, 31); in mice, loss of GPAT4 (which was initially identified as AGPAT6) is associated with the nearly complete absence of lipids in milk and the absence of CLD in mammary epithelial cells (30, 32), with apparently negligible effects on adipose tissue lipids (30).

Less is known about the identities of the enzymes catalyzing conversion of LPA to phosphatidic acid (PA) or PA to DAG in mammary epithelial cells. Acylation of LPA at the sn-2 position to form PA is catalyzed by members of family of 1-acylglycerol-3-phosphate acyltransferases (AGPAT) (29). Currently, only two members of this family have validated AGPAT activity. Other family members, such as AGPAT6 (see above) and AGPAT8, appear to possess different, or additional, acyltransferase activities (29). As yet, there is no clear indication which members of the AGPAT family catalyze PA formation in the mammary gland. However, high expression levels of GPAT4/AGPAT6 in mammary glands of lactating animals raise the possibility that it may be responsible for both LPA and PA biosynthesis (31). Members of the Lipin family of phosphatidate phosphatases catalyze the conversion of PA to DAG (29). Evidence in cattle, showing that lipin-1 transcripts are relatively abundant in mammary glands of lactating animals, have led to suggestions that this isoform is responsible for the synthesis of DAG used in milk lipid production. However, the importance of lipin-1 in this process has not been validated by loss- or gain-of-function studies.

TAG stabilization

Members of the perilipin (*PLIN*) family of CLD-associated proteins play essential functions in regulating cellular TAG levels (8, 33, 34). Five *PLIN* family members with different functional activities have been identified in eukaryotic cells: *PLIN1* (perilipin), *PLIN2* (adipophilin/ADRP), *PLIN3* (TIP47/mannose-6-phosphate receptor-binding protein 1), *PLIN4* (S3-12), and *PLIN5* (OxPAT/lipid storage droplet protein 5) (34–36). A primary function of *PLIN* proteins is the regulation of lipolysis by controlling lipase access to the TAG core of CLD (33, 37–39). Perilipin 2, which appears to be the primary *PLIN* family member expressed by mammary epithelial cells (16, 40–42), is an abundant protein on lipid droplets isolated from the milk of rodents, cattle, and humans (16, 43, 44). *PLIN2* transcripts are selectively enriched in mammary epithelial cells in the mouse mammary gland relative to other cell types (42), and their levels undergo about a 30-fold increase during mammary gland differentiation (42). Time course analyses, showing that the pattern of *PLIN2* transcript expression in the differentiating mammary gland closely correlates with CLD appearance, growth, and accumulation, implicate *PLIN2* as a physiological regulator of CLD production (42). Consistent with this conclusion, *PLIN2* deficiency impairs CLD accumulation in mammary epithelial cells of mice without affecting levels of the milk

protein β -casein (45). Evidence from mammary epithelial cells of intact mice (45), and from cultured HEK293 cells (39), showing that PLIN2 prevents binding of adipose TAG lipase to CLD suggest that it promotes milk production by stabilizing TAG against lipolysis (Figure 1).

De novo fatty acid synthesis

The fatty acid substrates needed for milk lipid synthesis are derived *de novo* from glucose, or obtained by transfer from the serum (46). Coordinate increases in the activities of enzymes involved in *de novo* fatty acid synthesis (47, 48) and transcript levels of genes encoding these enzymes (49, 50) have been documented in differentiating mammary glands of laboratory animals. Although the exact timing varies between species, induction of these enzymes occurs toward the end of pregnancy or at the beginning of lactation, with expression levels remaining elevated during lactation to maintain milk lipid production (48, 49). The importance of *de novo* fatty acid synthesis in regulating CLD production is suggested by studies of mice lacking protein kinase B (AKT1) (51). AKT1-dependent signaling influences the synthesis of glycerol and lipid from glucose by modulating glucose uptake (3, 51–53) and regulating the activity ATP-citrate lyase, a key regulatory enzyme in *de novo* fatty acid synthesis (54, 55). Mammary epithelial cells in AKT1-null mice exhibit normal morphology and milk protein expression, but their ability to produce CLD is impaired (51). Conversely, in transgenic mice overexpressing constitutively activated AKT1, there is precocious and pronounced accumulation of large CLD in differentiating milk-secreting cells and significant increases in the fat content of milk (3). Collectively, these data argue for a central role for AKT1 in regulating TAG formation in milk-secreting cells by increasing *de novo* glycerol and fatty acid synthesis, and through activation of glucose uptake (Figure 1) (51). These effects of AKT appear to be isozyme specific, as deficiencies in AKT-2 or AKT-3 do not significantly affect mammary gland properties or milk lipid formation, despite altering the metabolic properties of other cell types (51).

Mechanisms of milk lipid secretion

Milk and serum lipids are secreted by distinctly different mechanisms. Serum lipids are secreted by vesicle-mediated exocytosis from hepatocytes or enterocytes as soluble lipoprotein particles (56). Lipoprotein particle synthesis and packaging into secretory vesicles occurs within the ER and Golgi (56–58); thus, serum lipids can be viewed as originating within an external compartment. In contrast, milk lipid secretion occurs by an apocrine-like mechanism, involving apical plasma membrane envelopment of intact CLD, producing membrane bilayer-coated structures known as milk fat globules (MFG) (6, 59). Milk lipids thus remain within the cytoplasmic compartment, and in contact with membrane elements, even after secretion.

Two models have been proposed to explain the process by which CLD undergo envelopment and secretion. In the first, CLD become progressively surrounded by the apical plasma membrane by a process that may be analogous to the budding of viral particles (60, 61). Consistent with this ‘budding’ model, immunocytochemical evidence indicates that the majority of the MFG membrane envelope is derived from the apical plasma membrane (62). The second model differs from the first in that CLD membrane envelopment is coupled to fusion of peripherally associated secretory vesicles with the apical plasma membrane (59). In this model, the MFG membrane bilayer is hypothesized to be composed of both apical plasma membrane and secretory vesicle membrane elements. Although the weight of current evidence favors the ‘budding’ model (6), definitive evidence is lacking for either model. Moreover, observations of size and lipid composition differences in MFG (63) raise the possibility that milk lipids may be secreted by more than one mechanism. Nevertheless, a common feature of both models is the interaction of CLD with membrane elements;

consequently, identifying the mechanisms mediating such interactions is essential for understanding how milk lipid secretion occurs.

CLD-membrane interactions

CLD are likely to exist in close contact with membrane structures at all times within cells (11, 20, 61, 64), and there is considerable evidence that they form specialized contacts with elements of the apical plasma membrane during milk lipid secretion. In non-lactating animals, CLD appear to be randomly distributed within the cytoplasm of mammary epithelial cells (19). However, once lactation is initiated, they are found predominantly along the inner face of the apical plasma membrane (19, 42). Ultrastructural studies have shown that apical membrane-associated CLD are separated from the membrane bilayer by a 10–20-nm-thick layer of electron dense matrix material (20). Material of similar appearance also separates the lipid droplet surface from the membrane enveloping secreted MFG (20, 65). Matrix material has not been observed in association with CLD in non-secreting cells, nor is it detected on CLD located in other regions of lactating mammary epithelial cells (59), raising the possibility that its formation is secretion dependent, and that it represents structural linkages between CLD and apical membrane elements. Although its composition has not been fully defined, the matrix material associated with membranes surrounding human, bovine, caprine, and mouse MFG are uniquely enriched in three proteins: butyrophilin (BTN1A1/BTN), a receptor glycoprotein member of the immunoglobulin super-family (66, 67); xanthine oxidoreductase (XOR), a homodimeric purine oxidase that is highly expressed in mammary epithelial cells (68); and PLIN2, which as mentioned earlier, is a CLD-associated protein that is abundantly expressed in mammary epithelial cells and that contributes to CLD production (42, 69). Biochemical, localization, and binding assay evidence indicates that these proteins can form a stable complex with each other, and gene deletion and dominant-negative experiments have shown that each protein is important for milk lipid secretion (70–72). However, the molecular determinants mediating BTN, XOR, and PLIN2 interactions, and the mechanism by which these interactions mediate CLD envelopment and secretion, remain unknown, and alternative mechanisms have been suggested (72, 73). Three models have been proposed to explain how CLD interact with the apical membrane on the basis of structure-function mapping and high-resolution imaging of BTN and PLIN2 (Figure 2).

Tripartite model

This model envisions that CLD-membrane interactions are mediated by PLIN2 on the CLD surface binding to a complex of BTN and XOR located on the cytoplasmic face of the apical plasma membrane (6) (Figure 2). Evidence that BTN and XOR form functionally important linkages is suggested by observations that they are found in constant molar ratios on MFG membranes of cattle throughout lactation and that they can be cross-linked to each other using bifunctional cross-linking reagents (6). Importantly, *in vitro* binding assays showing that purified XOR binds to the C-terminal region (CTR) of BTN with relative high affinity (74) provide direct evidence that BTN and XOR are inherently able to interact with each other to form stable contacts.

Butyrophilin is a type 1 transmembrane protein composed of an externally oriented N-terminal region (NTR) consisting of two Ig folds, and a multidomain C-terminal cytoplasmic region consisting of a stem domain, a B30.2 domain, and a C-terminal cytoplasmic tail (74–76). XOR has been shown to bind stoichiometrically, and selectively, to the B30.2 domain of mouse BTN1A1, the BTN family member expressed in mammary epithelial cells (74). Mutations within the N- or C-terminal portions of B30.2 domain disrupt XOR binding (74), suggesting that binding requires the entire domain and is not mediated by individual submotifs within the domain. B30.2 domains are β -sheet structures containing SPRY and

PRY subdomains that are thought to be protein-binding modules. Although structurally similar B30.2 domains are also found in other BTN family members (BTN2 and BTN3), as well as in tripartite motif (TRIM) proteins (76) and the stonefish toxin, stonutoxin (77), to date only the BTN1 B30.2 domain appears to be capable of forming a stable complex with XOR (74). Sequence variability within the protein-binding motifs of B30.2 domain proteins has led to suggestions that individual B30.2 domains may have evolved to recognize specific binding partners. Thus, it is possible that the BTN1A1 B30.2 domain may be a specific XOR binding partner.

Despite the strong *in vitro* binding evidence, the physiological significance of XOR-BTN interactions remains uncertain. CLD interaction with the apical plasma membrane is hypothesized to be initiated by BTN oligomerization, induced by the binding of XOR (6). Data showing that the homodimeric XOR binds two BTN-B30.2 monomers or possibly one BTN-B30.2 dimer (74) support the concept that XOR and BTN can form higher-order structures. However, the C-terminal cytoplasmic region of BTN containing the stem and cytoplasmic tail domains, in addition to the B30.2 domain, is able to dimerize in the absence of XOR, possibly through interactions between α helical elements within the stem domain (74). Thus, it is possible that both homotypic BTN-BTN interactions and heterotypic XOR-BTN interactions may govern the interactions between BTN and XOR that lead to higher-order structure formation. Significantly, discrete BTN-BTN or BTN-XOR complexes greater than second order have yet to be detected, although heating in SDS induces aggregation of full-length BTN (74). It is unclear whether failure to detect distinct higher-order structures characteristic of BTN-BTN or XOR-BTN oligomers reflects the fact that the correct concentrations and/or conditions required for oligomer formation were not achieved, or that the cytoplasmic domain of BTN is insufficient for oligomerization. Detailed mapping of XOR-BTN and BTN-BTN binding determinants and careful biophysical analyses of these interactions should help resolve conceptual questions related to the role XOR-induced BTN oligomerization plays in milk lipid secretion.

The concept that XOR binds to the apical plasma membrane through its interactions with BTN may also be too simplistic. XOR is found on the limited number of MFG present in milk from BTN-null mice (74); thus, additional, or alternative, mechanisms may be involved in the recruitment of XOR to the apical membrane. Several observations suggest that membrane-associated redox activities contribute to the ability of XOR to bind to the apical membrane. First, the association of XOR with the apical plasma membrane is dynamically regulated by the secretory activity of the mammary gland (78). Second, XOR undergoes reversible thiol oxidation-dependent conversion from a dehydrogenase (XD) to an oxidase (XO) that results in conformation changes that expose a hydrophobic domain (79, 80). Histochemical and biochemical studies indicate that the thiol-oxidized (XO) conformation is enriched in secreted MFG, whereas thiol-reduced XOR is the predominant form of the enzyme in the cytoplasm of mammary epithelial cells (68, 81). Third, apical membrane preparations from lactating mammary tissue (82) and membranes isolated from secreted MFG (68) are reported to contain thiol oxidase activity that converts XD to XO. More recent studies suggest that the flavin-linked sulfhydryl oxidase, quiescin-sulfhydryl oxidase-1 (QSX1), is responsible for the majority of thiol oxidase activity in bovine milk (83). Members of the quiescin-sulfhydryl oxidase (QSOX) family are known to localize to the ER and the plasma membrane (83), raising the possibility that QSX1 or a QSOX family member may play a role in XOR oxidation coupled to milk lipid secretion. Whether thiol-oxidized XOR binds to BTN, or to some other membrane component, the presence of BTN nevertheless appears to stabilize XOR membrane interactions, as significantly more XOR is membrane-associated in MFG from wild-type mice than in MFG from BTN-null mice (74). Identifying the enzyme responsible for converting XOR from the XD to XO form is

essential for understanding how XOR binds to the apical membrane and for understanding how this process possibly contributes to milk lipid secretion.

BTN model

Evidence from freeze-fracture replica immunolabeling (FRIL) of isolated MFG has challenged the tripartite model, suggesting instead that BTN-BTN interactions are solely responsible for coupling CLD to the apical plasma membrane (73) (Figure 2). FRIL analysis of the topological distribution of PLIN2, BTN, and XOR on MFG shows that they exhibit divergent localizations that are inconsistent with the concept that they form a tripartite complex. Immunogold-labeled BTN was detected on the cytoplasmic facing surface (P-face) of the phospholipid monolayer surrounding the CLD core, and on the external facing surface (E-face) of the membrane bilayer. BTN labeling on the membrane bilayer E-face localized to a network of ridges that were juxtaposed and spatially matched to the BTN distribution on the P-face of CLD (73). In contrast, immunogold-labeled XOR localized only to the P-face of the CLD monolayer and was diffusely distributed on the monolayer surface, while PLIN2 immunolocalized to the cytoplasmic faces of the membrane bilayer and the CLD monolayer (73). The difficulty in fitting these data to the tripartite model led to the alternative proposal that homotypic interactions between BTN molecules located on the CLD surface and the apical membrane mediate CLD secretion (73). Although this novel model is consistent with functional evidence that BTN is required for CLD secretion (70), it fails to explain how an integral type I membrane glycoprotein such as BTN becomes enriched on the CLD surface; the extensive biochemical evidence documenting that XOR binds to BTN (74, 75, 78); or the *in vivo* evidence showing that disrupting XOR or PLIN2 functions impair CLD secretion (71, 72). Nevertheless, findings showing the presence of a network of ridges enriched in BTN on the membrane bilayer surrounding MFG suggest that BTN interacts to form higher-order structures with specific macromolecular organization. What determines the organization of the BTN ridges and whether such organization reflects the underlying structure of the machinery involved in milk lipid secretion remain to be determined. However, the organization of BTN into spatially distinct regions on the membranes surrounding secreted MFG is consistent with the concept that it can oligomerize, and that its oligomerization may be functionally relevant.

PLIN2 model

PLIN2 is composed of functionally and structurally distinct NTR and CTR (84). The NTR is composed of a PAT domain, which is a region of sequence homology with other PLIN family members that mediates proteasomal degradation (85) and possibly regulates lipase association functions (85, 86), and a putative 11-mer helical repeat region that appears to be responsible for CLD binding (36, 87, 88). The CTR encodes an independently folding four-helix bundle domain with an adjacent hydrophobic motif containing a unique α/β fold (72). This bipartite structural organization makes PLIN2 an ideal candidate to function as an adaptor between CLD and the apical membrane elements involved in milk lipid secretion. Evidence that the PLIN2 CTR plays an important role in regulating milk lipid secretion is suggested by studies in which mutant PLIN2 lacking the CTR was expressed in mammary epithelial cells of lactating mice (72). Mammary epithelial cells expressing this mutant possessed CLD and the mutant protein correctly localized to the CLD surface; however, secretion of CLD coated with the mutant protein was impaired relative to that of CLD coated with exogenously expressed recombinant full-length PLIN2, or with endogenous PLIN2 (72).

Details about the role the PLIN2 CTR plays in milk lipid secretion are limited. However, helix bundle motifs are known to reversibly bind lipids (89), and several lines of evidence indicate that the PLIN2 CTR has membrane-binding functions. First, freeze-fracture studies

demonstrated that in addition to being on the CLD surface, PLIN2 is found on the cytoplasmic leaflets of the plasma and ER membranes (11). Second, the PLIN2 CTR localizes to the plasma membrane, but not to CLD, when stably expressed in cultured cells (72), whereas the PLIN2 NTR selectively localizes to the CLD surface (72, 87). Finally, liposome-binding assays demonstrated that the PLIN2 CTR directly binds to phospholipid membranes, through charge-dependent interactions, possibly involving residues within helices 3 and 4 of the four-helix bundle (72). Collectively, these observations indicate that structural features within the PLIN2 CTR direct its membrane-binding functions, and that the PLIN2 CTR binds membranes through direct interactions with phospholipids (Figure 2). These data led to the proposal that interactions between the PLIN2 CTR four-helix bundle domain and the inner phospholipid leaflet of the apical plasma membrane mediate membrane docking of CLD, and possibly initiate the envelopment processes that lead to their secretion (84) (Figure 2).

CLD membrane envelopment

It is unknown how the apical membrane envelops CLD during milk lipid secretion. In other cellular functions involving membrane shape changes, such as endocytosis, vesicle formation, organelle biogenesis, and viral budding, membrane curvature is driven by protein-phospholipid interactions that perturb the bilayer organization and/or by oligomerization of membrane-associated scaffolding proteins that impart bending (90). Although the membrane deformations involved in vesicle formation or viral budding occur on a much smaller scale (nm) than those associated with CLD envelopment (μm), there is evidence that the principles, and in some cases the molecules, governing both sets of processes may be similar. First, CLD may provide a physical template for membrane-bending processes associated with their envelopment. Because CLD in mammary epithelial cells range in diameter from <1 micron to >10 microns in diameter, envelopment mechanisms must be able to accommodate a wide range of physical dimensions. The different bending geometries and stabilization forces associated with enveloping structures with different sizes suggest that CLD curvature, and the corresponding organization of molecules arrayed on their surface, may provide the appropriate architectural template required to match membrane-bending geometries to CLD of different dimensions. Ultrastructural experiments showing that CLD can be partially, or completely, wrapped by membranes of the ER provide further evidence that CLD can directly induce membrane bending (10). An implication of these findings is that membrane deformation processes associated with CLD envelopment are not specific to the plasma membrane; instead, the ability to bend membrane bilayers may be an inherent property of CLD. Consequently, it is possible that the lipid bilayer perturbations caused by contact with CLD molecules may be the mechanism that initiates their envelopment during milk lipid secretion.

Second, proteins containing helical bundle motifs are known to be capable of deforming and bending membranes (91, 92). The abundance of PLIN2 on CLD in mammary epithelial cells (16), and its ability to bind to membranes (11, 72), possibly through interactions between its C-terminal four-helix bundle motif and membrane phospholipids (72), implicate it in the induction of membrane bending associated with CLD envelopment. In support of this function, Plin3, which has a high degree of genetic and structural similarity to PLIN2 (36), has been shown to induce artificial membrane tubulation (93) and is known to be required for budding of certain types of virus (94). Although the four-helix bundle motifs of Plins 2 and 3 have not been shown directly to mediate membrane bending, the observations that binding of the PLIN2 four-helix bundle domain to membrane phospholipids is mediated by electrostatic interactions is consistent with earlier suggestions that such interactions may be a common feature of proteins that mediate budding in other systems (95).

Third, for many membrane-bending mechanisms, scaffolding proteins are recruited to sites of curvature to help stabilize membrane deformation (90). Lateral interactions between individual BTN molecules and XOR-BTN complexes at the apical membrane are hypothesized to form scaffolding required for CLD envelopment (74). This concept is supported by immunofluorescence and electron microscopic evidence showing enrichment of BTN and XOR on the apical sides of budding CLD in mammary glands of lactating cattle and mice (96, 97), and by immunofluorescence analyses showing that BTN, XOR, and PLIN2 selectively localize near one another at sites of CLD secretion on the apical plasma membrane of lactating mice (78). XOR enrichment on the apical plasma membrane and at sites of CLD secretion appears to be regulated by secretory activity (78), and to depend in part on the presence of BTN (74). These observations implicate recruitment of XOR to sites of CLD-membrane interaction as a possible mechanism regulating assembly and/or stabilization of scaffolding structures involved in CLD envelopment. However, additional studies are needed to define the molecular organization of the XOR-BTN complexes, and to understand how their scaffolding properties are regulated and how they contribute to CLD envelopment.

Summary

Milk lipids are a rich energy source for developing neonates, and mammals have evolved efficient lipid biosynthetic and secretion mechanisms to meet the postnatal growth demands of their young. Although the biochemical steps involved in milk lipid synthesis have been known for decades (98), the identities of the genes mediating these steps and the molecular physiology of milk lipid production have only recently begun to be understood in detail. A central concept derived from studies of transgenic mice is that milk lipid synthesis and secretion appear to play integral roles in mammary gland form and function, and that interference with these processes leads to complete lactation failure (26, 27, 30, 32, 45, 70, 71, 99). Whether the same is true for other species is uncertain, as the metabolic needs and survival of neonatal mice may be particularly dependent on high milk energy content provided by lipids (100, 101). However, gene deletion studies showing that disrupting the synthesis (27, 30) or stabilization of TAG (45) interferes with mammary alveoli maturation during pregnancy suggest that balanced lipid metabolism, particularly those processes involved in milk lipid production, are essential for normal mammary gland development. TAG synthesis precursors, including fatty acids, DAG, PA, and LPA, are known to have cell signaling and gene regulator functions (29). Thus, it is possible that milk lipid synthesis, through the actions of key intermediates, may indirectly contribute to the regulation of mammary gland development.

The mechanism of milk lipid secretion incorporates several features that distinguish it from other apocrine secretion mechanisms that have been described. First, if it is assumed that CLD are components of the cytoplasm, then milk lipid secretion may be the only major secretory pathway that is truly apocrine. Although apocrine secretion processes have been described in other glandular systems, these mechanisms of secretion appear to be hybrids of apocrine and exocrine secretion (102), and the contribution of apocrine processes to the composition of their secretion products is unclear. In contrast, secretion of milk lipids by membrane envelopment of CLD appears to account for the majority, if not all, of the lipid secreted into milk. Second, the intimate association of CLD with the apical membrane during milk lipid secretion appears to distinguish it from other apocrine secretion processes, which are characterized by capture of soluble protein and/or secretory vesicle cargo within membrane blebs without evidence of membrane interaction (102, 103). At present, it is unclear to what extent the cargo influences the formation of these membrane blebs. In contrast, multiple lines of evidence indicate that direct interactions between specific CLD surface proteins and elements of the apical membrane are critical for apocrine secretion of

CLD, possibly serving as molecular template to guide this process. Third, rather than being simply lipid storage structures, CLD are now recognized as having organelle-like properties (10, 104, 105). Thus, milk lipid secretion maybe a unique example of apocrine secretion of an organelle.

Why mammary epithelial cells evolved to use a membrane envelopment mechanism for secreting lipids rather than the ER and Golgi exocrine pathway used for serum lipid secretion is unclear. One possibility is that membrane envelopment of CLD may provide a more efficient pathway for lipid secretion than the ER-Golgi pathway. Although lipid secretion through the ER-Golgi pathway can be significant (serum lipid concentration in humans range from 2% to 10%), milk lipid concentration in many species is well over 10%. In addition, compared with serum lipoprotein particles, MFG have markedly larger diameters (~3–5 μm on average compared with ~0.2 μm for chylomicrons). Consequently, the corresponding volume of lipid contained within a MFG is about 10 000 times that of chylomicron particle, which is consistent with an enormous gain in lipid secretion efficiency that may be required to meet neonatal growth demands.

A second possibility is that MFG have been proposed to play biological functions beyond providing a rich source of energy for neonates (106, 107). In addition to providing structural support, the membrane enveloping MFG is thought to possess bioactive components that potentially contribute to the protection of infants against bacterial infection and possibly their nutrition (107, 108). The concept that MFG are actually secreted organelles also suggests the provocative possibility that MFG are sites of biological reactions important for infant health. It has been known for over 30 years that MFG membranes contain redox enzymes, possibly derived from the ER (65). More recently, proteomic analysis has identified additional enzymes and proteins with possible biological activities on MFG membranes (109) and provided evidence that many of these proteins originate from enveloped CLD (16, 110, 111).

In conclusion, efforts to understand the molecular frameworks regulating lipid synthesis and secretion have led to the identification of critical enzyme and protein determinants of these processes, and are beginning to uncover their underlying structural mechanisms. Importantly, these studies have provided new insight into possible roles lipid metabolism may play in mammary gland development and function, and the potential biological functions of the secreted lipid droplets. However, many important details remain to be learned about the mechanisms controlling CLD biogenesis and secretion, and how these processes are regulated at the physiological level to ensure sufficient milk lipid production during lactation.

Acknowledgments

This study was supported by grants from the National Institutes of Health, 2RO1-HD045962 and PO1-HD38129, to JLM. The author thanks B. Chong, J. Monks, and D. Orlicky for helpful comments and discussions.

References

1. Oftedal OT. Use of maternal reserves as a lactation strategy in large mammals. *Proc Nutr Soc.* 2000; 59:99–106. [PubMed: 10828179]
2. Allen JC, Keller RP, Archer P, Neville MC. Studies in human lactation: milk composition and daily secretion rates of macro-nutrients in the first year of lactation. *Am J Clin Nutr.* 1991; 54:69–80. [PubMed: 2058590]
3. Schwertfeger KL, McManaman JL, Palmer CA, Neville MC, Anderson SM. Expression of constitutively activated Akt in the mammary gland leads to excess lipid synthesis during pregnancy and lactation. *J Lipid Res.* 2003; 44:1100–1112. [PubMed: 12700340]

4. Rudolph MC, Neville MC, Anderson SM. Lipid synthesis in lactation: diet and the fatty acid switch. *J Mammary Gland Biol Neoplasia*. 2007; 12:269–281. [PubMed: 18027074]
5. Dils, R.; Clark, S.; Knudsen, J. Comparative aspects of milk fat synthesis. In: Peaker, M., editor. *Comparative aspects of lactation*. London: Academic Press; 1977. p. 43-55.
6. Mather IH, Keenan TW. Origin and secretion of milk lipids. *J Mammary Gland Biol Neoplasia*. 1998; 3:259–273. [PubMed: 10819513]
7. Greenberg AS, Coleman RA, Kraemer FB, McManaman JL, Obin MS, Puri V, Yan QW, Miyoshi H, Mashek DG. The role of lipid droplets in metabolic disease in rodents and humans. *J Clin Invest*. 2011; 121:2102–2110. [PubMed: 21633178]
8. Murphy DJ. The biogenesis and functions of lipid bodies in animals, plants and microorganisms. *Prog Lipid Res*. 2001; 40:325–438. [PubMed: 11470496]
9. Stein O, Stein Y. Lipid synthesis, intracellular transport, and secretion. II. Electron microscopic radioautographic study of the mouse lactating mammary gland. *J Cell Biol*. 1967; 34:251–263. [PubMed: 6033535]
10. Martin S, Parton RG. Lipid droplets: a unified view of a dynamic organelle. *Nat Rev Mol Cell Biol*. 2006; 7:373–378. [PubMed: 16550215]
11. Robenek H, Hofnagel O, Buers I, Robenek MJ, Troyer D, Severs NJ. Adipophilin-enriched domains in the ER membrane are sites of lipid droplet biogenesis. *J Cell Sci*. 2006; 119(Pt 20): 4215–4224. [PubMed: 16984971]
12. Wan HC, Melo RC, Jin Z, Dvorak AM, Weller PF. Roles and origins of leukocyte lipid bodies: proteomic and ultrastructural studies. *FASEB J*. 2007; 21:167–178. [PubMed: 17135363]
13. Weiss SB, Kennedy EP, Kiyasu JY. The enzymatic synthesis of triglycerides. *J Biol Chem*. 1960; 235:40–44. [PubMed: 13843753]
14. Yen CL, Stone SJ, Koliwad S, Harris C, Farese RV Jr. Thematic review series: glycerolipids. DGAT enzymes and triacylglycerol biosynthesis. *J Lipid Res*. 2008; 49:2283–2301. [PubMed: 18757836]
15. Suckling KE, Stange EF. Role of acyl-CoA: cholesterol acyltransferase in cellular cholesterol metabolism. *J Lipid Res*. 1985; 26:647–671. [PubMed: 3897424]
16. Wu CC, Howell KE, Neville MC, Yates JR 3rd, McManaman JL. Proteomics reveal a link between the endoplasmic reticulum and lipid secretory mechanisms in mammary epithelial cells. *Electrophoresis*. 2000; 21:3470–3482. [PubMed: 11079566]
17. Ozeki S, Cheng J, Tauchi-Sato K, Hatano N, Taniguchi H, Fujimoto T. Rab18 localizes to lipid droplets and induces their close apposition to the endoplasmic reticulum-derived membrane. *J Cell Sci*. 2005; 118(Pt 12):2601–2611. [PubMed: 15914536]
18. Keenan TW, Dylewski DP, Ghosal D, Keon BH. Milk lipid globule precursor release from endoplasmic reticulum reconstituted in a cell-free system. *Eur J Cell Biol*. 1992; 57:21–29. [PubMed: 1639090]
19. Hollmann, KH. Cytology and fine structure of the mammary gland. In: Larson, BL.; Smith, VR., editors. *Lactation*. Vol. Vol I. New York: Academic Press; 1974. p. 3-95.
20. Comparative mammary fine structure. In: Wooding, FBP., editor; Peaker, M., editor. *Comparative aspects of lactation*. London: Academic Press; 1977. p. 1-41.
21. Clermont Y, Xia L, Rambourg A, Turner JD, Hermo L. Structure of the Golgi apparatus in stimulated and nonstimulated acinar cells of mammary glands of the rat. *Anat Rec*. 1993; 237:308–317. [PubMed: 8291683]
22. Kennedy EP. Metabolism of lipides. *Annu Rev Biochem*. 1957; 26:119–148. [PubMed: 13488391]
23. Coleman RA, Lee DP. Enzymes of triacylglycerol synthesis and their regulation. *Prog Lipid Res*. 2004; 43:134–176. [PubMed: 14654091]
24. Cases S, Stone SJ, Zhou P, Yen E, Tow B, Lardizabal KD, Voelker T, Farese RV Jr. Cloning of DGAT2, a second mammalian diacylglycerol acyltransferase, and related family members. *J Biol Chem*. 2001; 276:38870–38876. [PubMed: 11481335]
25. Cases S, Smith SJ, Zheng YU, Myers HM, Lear SR, Sande E, Novak S, Collins C, Welch CB, Lusis AJ, Erickson SK, Farese RV Jr. Identification of a gene encoding an acyl CoA:diacylglycerol acyltransferase, a key enzyme in triacylglycerol synthesis. *Proc Natl Acad Sci USA*. 1998; 95:13018–13023. [PubMed: 9789033]

26. Smith SJ, Cases S, Jensen DR, Chen HC, Sande E, Tow B, Sanan DA, Raber J, Eckel RH, Farese RV. Obesity resistance and multiple mechanisms of triglyceride synthesis in mice lacking Dgat. *Nat Genet.* 2000; 25:87–90. [PubMed: 10802663]
27. Cases S, Zhou P, Shillingford JM, Wiseman BS, Fish JD, Angle CS, Hennighausen L, Werb Z, Farese RV Jr. Development of the mammary gland requires DGAT1 expression in stromal and epithelial tissues. *Development.* 2004; 131:3047–3055. [PubMed: 15163627]
28. Grisart B, Farnir F, Karim L, Cambisano N, Kim JJ, Kvasz A, Mni M, Simon P, Frère JM, Coppieters W, Georges M. Genetic and functional confirmation of the causality of the DGAT1 K232A quantitative trait nucleotide in affecting milk yield and composition. *Proc Natl Acad Sci USA.* 2004; 101:2398–2403. [PubMed: 14983021]
29. Takeuchi K, Reue K. Biochemistry, physiology, and genetics of GPAT, AGPAT, and lipin enzymes in triglyceride synthesis. *Am J Physiol Endocrinol Metab.* 2009; 296:E1195–E1209. [PubMed: 19336658]
30. Beigneux AP, Vergnes L, Qiao X, Quatela S, Davis R, Watkins SM, Coleman RA, Walzem RL, Philips M, Reue K, Young SG. Agpat6 – a novel lipid biosynthetic gene required for triacylglycerol production in mammary epithelium. *J Lipid Res.* 2006; 47:734–744. [PubMed: 16449762]
31. Bionaz M, Loor JJ. ACSL1, AGPAT6, FABP3, LPIN1, and SLC27A6 are the most abundant isoforms in bovine mammary tissue and their expression is affected by stage of lactation. *J Nutr.* 2008; 138:1019–1024. [PubMed: 18492828]
32. Chen YQ, Kuo MS, Li S, Bui HH, Peake DA, Sanders PE, Thibodeaux SJ, Chu S, Qian YW, Zhao Y, Bredt DS, Moller DE, Konrad RJ, Beigneux AP, Young SG, Cao G. AGPAT6 is a novel microsomal glycerol-3-phosphate acyltransferase. *J Biol Chem.* 2008; 283:10048–10057. [PubMed: 18238778]
33. Wolins NE, Brasaemle DL, Bickel PE. A proposed model of fat packaging by exchangeable lipid droplet proteins. *FEBS Lett.* 2006; 580:5484–5491. [PubMed: 16962104]
34. Ducharme NA, Bickel PE. Lipid droplets in lipogenesis and lipolysis. *Endocrinology.* 2008; 149:942–949. [PubMed: 18202123]
35. Lu X, Gruia-Gray J, Copeland NG, Gilbert DJ, Jenkins NA, Londos C, Kimmel AR. The murine perilipin gene: the lipid droplet-associated perilipins derive from tissue-specific, mRNA splice variants and define a gene family of ancient origin. *Mamm Genome.* 2001; 12:741–749. [PubMed: 11641724]
36. Brasaemle DL. The perilipin family of structural lipid droplet proteins: stabilization of lipid droplets and control of lipolysis. *J Lipid Res.* 2007; 48:2547–2549. [PubMed: 17878492]
37. Londos C, Sztalryd C, Tansey JT, Kimmel AR. Role of PAT proteins in lipid metabolism. *Biochimie.* 2005; 87:45–49. [PubMed: 15733736]
38. Sztalryd C, Bell M, Lu X, Mertz P, Hickenbottom S, Chang BHJ, Chan L, Kimmel AR, Londos C. Functional compensation for adipose differentiation-related protein (ADFP) by TIP47 in an adfp null embryonic cell line. *J Biol Chem.* 2006; 281:34341–34348. [PubMed: 16968708]
39. Listenberger LL, Ostermeyer-Fay AG, Goldberg EB, Brown WJ, Brown DA. Adipocyte differentiation-related protein reduces lipid droplet association of adipose triglyceride lipase and slows triacylglycerol turnover. *J Lipid Res.* 2007; 48:2751–2761. [PubMed: 17872589]
40. Brasaemle DL, Barber T, Wolins NE, Serrero G, Blanchette-Mackie EJ, Londos C. Adipose differentiation-related protein is an ubiquitously expressed lipid storage droplet-associated protein. *J Lipid Res.* 1997; 38:2249–2263. [PubMed: 9392423]
41. Heid HW, Moll R, Schwetlick I, Rackwitz HR, Keenan TW. Adipophilin is a specific marker of lipid accumulation in diverse cell types and diseases. *Cell Tissue Res.* 1998; 294:309–321. [PubMed: 9799447]
42. Russell TD, Palmer CA, Orlicky DJ, Fischer A, Rudolph MC, Neville MC, McManaman JL. Cytoplasmic lipid droplet accumulation in developing mammary epithelial cells: roles of adipophilin and lipid metabolism. *J Lipid Res.* 2007; 48:1463–1475. [PubMed: 17452747]
43. Heid HW, Schnolzer M, Keenan TW. Adipocyte differentiation-related protein is secreted into milk as a constituent of milk lipid globule membrane. *Biochem J.* 1996; 320(Pt 3):1025–1030. [PubMed: 9003395]

44. Spertino S, Cipriani V, De Angelis C, Giuffrida MG, Marsano F, Cavaletto M. Proteome profile and biological activity of caprine, bovine and human milk fat globules. *Mol Biosyst.* 2012; 8:967–974. [PubMed: 22193558]
45. Russell TD, Schaack J, Orlicky DJ, Palmer C, Chang BHJ, Chan L, McManaman JL. Adipophilin regulates maturation of cytoplasmic lipid droplets and alveolae in differentiating mammary glands. *J Cell Sci.* 2011; 124:3247–3253. [PubMed: 21878492]
46. Neville MC, Picciano MF. Regulation of milk lipid secretion and composition. *Annu Rev Nutr.* 1997; 17:159–183. [PubMed: 9240924]
47. Baldwin, RL.; Yang, YT. Enzymatic and metabolic changes in the development of lactation. In: Larson, BL.; Smith, VR., editors. *Lactation*. New York: Academic Press; 1974. p. 349–407.
48. Mellenberger RW, Bauman DE. Metabolic adaptations during lactogenesis. Fatty acid synthesis in rabbit mammary tissue during pregnancy and lactation. *Biochem J.* 1974; 138:373–379. [PubMed: 4154742]
49. Rudolph MC, McManaman JL, Hunter L, Phang T, Neville MC. Functional development of the mammary gland: use of expression profiling and trajectory clustering to reveal changes in gene expression during pregnancy, lactation, and involution. *J Mammary Gland Biol Neoplasia.* 2003; 8:287–307. [PubMed: 14973374]
50. Rudolph MC, McManaman JL, Phang T, Russell T, Kominsky DJ, Serkova NJ, Stein T, Anderson SM, Neville MC. Metabolic regulation in the lactating mammary gland: a lipid synthesizing machine. *Physiol Genomics.* 2007; 28:323–336. [PubMed: 17105756]
51. Boxer RB, Stairs DB, Dugan KD, Notarfrancesco KI, Portocarrero CP, Keister BA, Belka GK, Cho H, Rathmell JC, Thompson CB, Birnbaum MJ, Chodosh LA. Isoform-specific requirement for Akt1 in the developmental regulation of cellular metabolism during lactation. *Cell Metab.* 2006; 4:475–490. [PubMed: 17141631]
52. Kohn AD, Summers SA, Birnbaum MJ, Roth RA. Expression of a constitutively active Akt Ser/Thr kinase in 3T3-L1 adipocytes stimulates glucose uptake and glucose transporter 4 translocation. *J Biol Chem.* 1996; 271:31372–31378. [PubMed: 8940145]
53. Magun R, Burgering BM, Coffey PJ, Pardasani D, Lin Y, Chabot J, Sorisky A. Expression of a constitutively activated form of protein kinase B (c-Akt) in 3T3-L1 preadipose cells causes spontaneous differentiation. *Endocrinology.* 1996; 137:3590–3593. [PubMed: 8754791]
54. Berwick DC, Hers I, Heesom KJ, Moule SK, Tavare JM. The identification of ATP-citrate lyase as a protein kinase B (Akt) substrate in primary adipocytes. *J Biol Chem.* 2002; 277:33895–33900. [PubMed: 12107176]
55. Bauer DE, Hatzivassiliou G, Zhao F, Andreadis C, Thompson CB. ATP citrate lyase is an important component of cell growth and transformation. *Oncogene.* 2005; 24:6314–6322. [PubMed: 16007201]
56. Vance JE, Vance DE. Lipoprotein assembly and secretion by hepatocytes. *Annu Rev Nutr.* 1990; 10:337–356. [PubMed: 2200467]
57. Stein O, Stein Y. Lipid synthesis, intracellular transport, storage, and secretion. I. Electron microscopic radioautographic study of liver after injection of tritiated palmitate or glycerol in fasted and ethanol-treated rats. *J Cell Biol.* 1967; 33:319–339. [PubMed: 6039375]
58. Murphy DJ, Vance J. Mechanisms of lipid-body formation. *Trends Biochem Sci.* 1999; 24:109–115. [PubMed: 10203758]
59. Wooding FB. The mechanism of secretion of the milk fat globule. *J Cell Sci.* 1971; 9:805–821. [PubMed: 5148018]
60. Wooding FB. Milk microsomes, viruses, and the milk fat globule membrane. *Experientia.* 1972; 28:1077–1079. [PubMed: 4353034]
61. McManaman JL, Russell TD, Schaack J, Orlicky DJ, Robenek H. Molecular determinants of milk lipid secretion. *J Mammary Gland Biol Neoplasia.* 2007; 12:259–268. [PubMed: 17999166]
62. Mather IH, Jack LJ, Madara PJ, Johnson VG. The distribution of MUC1, an apical membrane glycoprotein, in mammary epithelial cells at the resolution of the electron microscope: implications for the mechanism of milk secretion. *Cell Tissue Res.* 2001; 304:91–101. [PubMed: 11383890]

63. Argov N, Wachsmann-Hogiu S, Freeman SL, Huser T, Lebrilla CB, German JB. Size-dependent lipid content in human milk fat globules. *J Agric Food Chem.* 2008; 56:7446–7450. [PubMed: 18656925]
64. Farese RV Jr, Walther TC. Lipid droplets finally get a little R-E-S-P-E-C-T. *Cell.* 2009; 139:855–860. [PubMed: 19945371]
65. Jarasch ED, Bruder G, Keenan TW, Franke WW. Redox constituents in milk fat globule membranes and rough endoplasmic reticulum from lactating mammary gland. *J Cell Biol.* 1977; 73:223–241. [PubMed: 856833]
66. Banghart LR, Chamberlain CW, Velarde J, Korobko IV, Ogg SL, Jack LJW, Vakharia VN, Mather IH. Butyrophilin is expressed in mammary epithelial cells from a single-sized messenger RNA as a type I membrane glycoprotein. *J Biol Chem.* 1998; 273:4171–4179. [PubMed: 9461613]
67. Vernet C, Boretto J, Mattéi MG, Takahashi M, Jack LJW, Mather IH, Rouquier S, Pontarotti P. Evolutionary study of multigenic families mapping close to the human MHC class I region. *J Mol Evol.* 1993; 37:600–612. [PubMed: 8114113]
68. McManaman JL, Neville MC, Wright RM. Mouse mammary gland xanthine oxidoreductase: purification, characterization, and regulation. *Arch Biochem Biophys.* 1999; 371:308–316. [PubMed: 10545219]
69. Russell TD, Palmer CA, Orlicky DJ, Bales ES, Chang BHJ, Chan L, McManaman JL. Mammary glands of adipophilin-null mice produce an amino-terminally truncated form of adipophilin that mediates milk lipid droplet formation and secretion. *J Lipid Res.* 2008; 49:206–216. [PubMed: 17921437]
70. Ogg SL, Weldon AK, Dobbie L, Smith AJ, Mather IH. Expression of butyrophilin (Btn1a1) in lactating mammary gland is essential for the regulated secretion of milk-lipid droplets. *Proc Natl Acad Sci USA.* 2004; 101:10084–10089. [PubMed: 15226505]
71. Vorbach C, Scriven A, Capecchi MR. The housekeeping gene xanthine oxidoreductase is necessary for milk fat droplet enveloping and secretion: gene sharing in the lactating mammary gland. *Genes Dev.* 2002; 16:3223–3235. [PubMed: 12502743]
72. Chong BM, Russell TD, Schaack J, Orlicky DJ, Reigan P, Ladinsky M, McManaman JL. The adipophilin C-terminus is a self-folding membrane binding domain that is important for milk lipid secretion. *J Biol Chem.* 2011; 286:23254–23265. [PubMed: 21383012]
73. Robenek H, Hofnagel O, Buers I, Lorkowski S, Schnoor M, Robenek MJ, Heid H, Troyer D, Severs NJ. Butyrophilin controls milk fat globule secretion. *Proc Natl Acad Sci USA.* 2006; 103:10385–10390. [PubMed: 16801554]
74. Jeong J, Rao AU, Xu J, Ogg SL, Hathout Y, Fenselau C, Mather IH. The PRY/SPRY/B30.2 domain of butyrophilin 1A1 (BTN1A1) binds to xanthine oxidoreductase: implications for the function of BTN1A1 in the mammary gland and other tissues. *J Biol Chem.* 2009; 284:22444–22456. [PubMed: 19531472]
75. Ishii T, Aoki N, Noda A, Adachi T, Nakamura R, Matsuda T. Carboxy-terminal cytoplasmic domain of mouse butyrophilin specifically associates with a 150-kDa protein of mammary epithelial cells and milk fat globule membrane. *Biochim Biophys Acta.* 1995; 1245:285–292. [PubMed: 8541302]
76. Abeler-Dorner L, Swamy M, Williams G, Hayday AC, Bas A. Butyrophilins: an emerging family of immune regulators. *Trends Immunol.* 2012; 33:34–41. [PubMed: 22030238]
77. Seto MH, Liu HL, Zajchowski DA, Whitlow M. Protein fold analysis of the B30.2-like domain. *Proteins.* 1999; 35:235–249. [PubMed: 10223295]
78. McManaman JL, Palmer CA, Wright RM, Neville MC. Functional regulation of xanthine oxidoreductase expression and localization in the mouse mammary gland: evidence of a role in lipid secretion. *J Physiol.* 2002; 545(Pt 2):567–579. [PubMed: 12456835]
79. Massey V, Schopfer LM, Nishino T, Nishino T. Differences in protein structure of xanthine dehydrogenase and xanthine oxidase revealed by reconstitution with flavin active site probes. *J Biol Chem.* 1989; 264:10567–10573. [PubMed: 2732238]
80. McManaman JL, Bain DL. Structural and conformational analysis of the oxidase to dehydrogenase conversion of xanthine oxidoreductase. *J Biol Chem.* 2002; 277:21261–21268. [PubMed: 11914370]

81. Frederiks WM, Marx F. A histochemical procedure for light microscopic demonstration of xanthine oxidase activity in unfixed cryostat sections using cerium ions and a semipermeable membrane technique. *J Histochem Cytochem.* 1993; 41:667–670. [PubMed: 8468447]
82. Clare DA, Blakistone BA, Swaisgood HE, Horton HR. Sulfhydryl oxidase-catalyzed conversion of xanthine dehydrogenase to xanthine oxidase. *Arch Biochem Biophys.* 1981; 211:44–47. [PubMed: 6946727]
83. Jaje J, Wolcott HN, Fadugba O, Cripps D, Yang AJ, Mather IH, Thorpe C. A flavin-dependent sulfhydryl oxidase in bovine milk. *Biochemistry.* 2007; 46:13031–13040. [PubMed: 17944490]
84. Chong BM, Reigan P, Mayle-Combs KD, Orlicky DJ, McManaman JL. Determinants of adipophilin function in milk lipid formation and secretion. *Trends Endocrinol Metab.* 2011; 22:211–217. [PubMed: 21592818]
85. Orlicky DJ, Degala G, Greenwood C, Bales ES, Russell TD, McManaman JL. Multiple functions encoded by the N-terminal PAT domain of adipophilin. *J Cell Sci.* 2008; 121(Pt 17):2921–2929. [PubMed: 18697835]
86. Wang H, Hu L, Dalen K, Dorward H, Marcinkiewicz A, Russell D, Gong D, Londos C, Yamaguchi T, Holm C, Rizzo MA, Brasaemle D, Sztalryd C. Activation of hormone-sensitive lipase requires two steps, protein phosphorylation and binding to the PAT-1 domain of lipid droplet coat proteins. *J Biol Chem.* 2009; 284:32116–32125. [PubMed: 19717842]
87. McManaman JL, Zabaronick W, Schaack J, Orlicky DJ. Lipid droplet targeting domains of adipophilin. *J Lipid Res.* 2003; 44:668–673. [PubMed: 12562852]
88. Targett-Adams P, Chambers D, Gledhill S, Hope RG, Coy JF, Girod A, McLauchlan J. Live cell analysis and targeting of the lipid droplet-binding adipocyte differentiation-related protein. *J Biol Chem.* 2003; 278:15998–16007. [PubMed: 12591929]
89. Narayanaswami V, Kiss RS, Weers PM. The helix bundle: a reversible lipid binding motif. *Comp Biochem Physiol A Mol Integr Physiol.* 2010; 155:123–133. [PubMed: 19770066]
90. Farsad K, Ringstad N, Takei K, Floyd SR, Rose K, De Camilli P. Generation of high curvature membranes mediated by direct endophilin bilayer interactions. *J Cell Biol.* 2001; 155:193–200. [PubMed: 11604418]
91. McMahon HT, Gallop JL. Membrane curvature and mechanisms of dynamic cell membrane remodelling. *Nature.* 2005; 438:590–596. [PubMed: 16319878]
92. Varkey J, Isas JM, Mizuno N, Jensen MB, Bhatia VK, Jao CC, Petrlova J, Voss JC, Stamou DG, Steven AC, Langen R. Membrane curvature induction and tubulation are common features of synucleins and apolipoproteins. *J Biol Chem.* 2010; 285:32486–32493. [PubMed: 20693280]
93. Bulankina AV, Deggerich A, Wenzel D, Mutenda K, Wittmann JG, Rudolph MG, Burger KN, Höning S. TIP47 functions in the biogenesis of lipid droplets. *J Cell Biol.* 2009; 185:641–655. [PubMed: 19451273]
94. Lopez-Vergès S, Camus G, Blot G, Beauvoir R, Benarous R, Berlioz-Torrent C. Tail-interacting protein TIP47 is a connector between Gag and Env and is required for Env incorporation into HIV-1 virions. *Proc Natl Acad Sci USA.* 2006; 103:14947–14952. [PubMed: 17003132]
95. Solon J, Gareil O, Bassereau P, Gaudin Y. Membrane deformations induced by the matrix protein of vesicular stomatitis virus in a minimal system. *J Gen Virol.* 2005; 86(Pt 12):3357–3363. [PubMed: 16298982]
96. Franke WW, Heid HW, Grund C, Winter S, Freudenstein C, Schmid E, Jarasch ED, Keenan TW. Antibodies to the major insoluble milk fat globule membrane-associated protein: specific location in apical regions of lactating epithelial cells. *J Cell Biol.* 1981; 89:485–494. [PubMed: 7019216]
97. Jarasch ED, Grund C, Bruder G, Heid HW, Keenan TW, Franke WW. Localization of xanthine oxidase in mammary-gland epithelium and capillary endothelium. *Cell.* 1981; 25:67–82. [PubMed: 6895049]
98. Neville MC, Walsh CT. Effects of xenobiotics on milk secretion and composition. *Am J Clin Nutr.* 1995; 61(Suppl.):687S–694S. [PubMed: 7879739]
99. Nagle CA, Vergnes L, Dejong H, Wang S, Lewin TM, Reue K, Coleman RA. Identification of a novel sn-glycerol-3-phosphate acyltransferase isoform, GPAT4, as the enzyme deficient in *Agpat6*^{-/-} mice. *J Lipid Res.* 2008; 49:823–831. [PubMed: 18192653]

100. Johnson MS, Thomson SC, Speakman JR. Limits to sustained energy intake. I. Lactation in the laboratory mouse *Mus musculus*. *J Exp Biol*. 2001; 204(Pt 11):1925–1935. [PubMed: 11441034]
101. Wahlig JL, Bales ES, Jackman MR, Johnson GC, McManaman JL, Maclean PS. Impact of high-fat diet and obesity on energy balance and fuel utilization during the metabolic challenge of lactation. *Obesity (Silver Spring)*. 2012; 20:65–75. [PubMed: 21720435]
102. Gesase AP, Satoh Y. Apocrine secretory mechanism: recent findings and unresolved problems. *Histol Histopathol*. 2003; 18:597–608. [PubMed: 12647810]
103. Aumuller G, Wilhelm B, Seitz J. Apocrine secretion - fact or artifact? *Ann Anat*. 1999; 181:437–446. [PubMed: 10560009]
104. Murphy S, Martin S, Parton RG. Lipid droplet-organelle interactions; sharing the fats. *Biochim Biophys Acta*. 2009; 1791:441–447. [PubMed: 18708159]
105. Fujimoto T, Parton RG. Not just fat: the structure and function of the lipid droplet. *Cold Spring Harb Perspect Biol*. 2011; 3:a004838. [PubMed: 21421923]
106. Hamosh M, Peterson JA, Henderson TR, Scallan CD, Kiwan R, Ceriani RL, Armand M, Mehta NR, Hamosh P. Protective function of human milk: the milk fat globule. *Semin Perinatol*. 1999; 23:242–249. [PubMed: 10405194]
107. Dewettinck K, Rombaut R, Thienpont N, Le TT, Messens K, Van Camp J. Nutritional and technological aspects of milk fat globule membrane material. *Int Dairy J*. 2008; 18:436–457.
108. Lopez C. Milk fat globules enveloped by their biological membrane: unique colloidal assemblies with a specific composition and structure. *Curr Opin Colloid Interf Sci*. 2011; 16:391–404.
109. Reinhardt TA, Lippolis JD. Developmental changes in the milk fat globule membrane proteome during the transition from colostrum to milk. *J Dairy Sci*. 2008; 91:2307–2318. [PubMed: 18487653]
110. Beller M, Thiel K, Thul PJ, Jackle H. Lipid droplets: a dynamic organelle moves into focus. *FEBS Lett*. 2010; 584:2176–2182. [PubMed: 20303960]
111. Ding Y, Wu Y, Zeng R, Liao K. Proteomic profiling of lipid droplet-associated proteins in primary adipocytes of normal and obese mouse. *Acta Biochim Biophys Sin*. 2012; 44:394–406. [PubMed: 22343379]

Figure 1. Molecular determinants of milk lipid formation

The immediate precursors of milk lipids are CLD. These organelle-like structures, which originate from specific ER domains, are composed of a TAG core that is surrounded by a phospholipid monolayer and coated with functionally specialized proteins. Perilipin 2 (PLIN2, indicated by the red dashed line surrounding the TAG core) is the most abundant CLD-associated protein in milk-secreting cells. By inhibiting adipose triglyceride lipase (ATGL)-mediated lipolysis of TAG to fatty acids (FA) and diacylglycerol (DAG), PLIN2 plays an essential role in stabilizing CLD. The TAG core is synthesized by sequential FA acylation of glycerol by four ER membrane-associated enzymes. The first step in TAG synthesis, the addition of FA to glycerol-3-phosphate (G-3-P) to form LPA, is specifically catalyzed by glycerol-3-phosphate-*O*-acyltransferase-4 (GPAT4). Loss of GPAT4 prevents milk lipid formation and lactation. The addition of FA to LPA to form PA is catalyzed by, as yet undefined, members of the 1-acylglycerol-3-phosphate-*O*-acyltransferase (AGPAT) family. Lipin1 catalyzes the removal of the phosphate group from PA to form DAG. The final step in TAG synthesis, the addition of FA to DAG, is specifically catalyzed by diacylglycerol-*O*-acyltransferase-1 (DGAT1). Loss of DGAT1 prevents milk lipid formation and lactation. Inset: The FA substrates for synthesis of milk lipids are derived from the diet, by mobilization from adipose stores or by *de novo* synthesis from glucose. Protein kinase-B1 (AKT1) regulates the *de novo* synthesis pathway, and disruption of its functions is associated with abnormalities in milk lipid production.

Figure 2. Mechanisms of milk lipid secretion

Three conceptual models of the mechanisms of milk lipid secretion have been proposed. The tripartite model predicts that CLD associate with the apical plasma membrane through interactions between PLIN2 on the CLD surface and a complex of butyrophilin1A1 (BTN1A1) and XOR on the apical membrane. The BTN1A1-XOR complex is proposed to be formed between a specific B 30.2 domain located within the CTR of BTN1A1 and unknown portions of XOR. PLIN2 is proposed to bind to the BTN1A1-XOR complex through specific domains located within its CTR, and induce clustering of the complex and membrane envelopment of CLD. The BTN-BTN model predicts that homotypic interactions between BTN1A1 molecules located on the CLD surface and the apical plasma membrane leads to the formation of BTN oligomers and membrane envelopment of CLD. The PLIN2-phospholipid model predicts that interactions between the C-terminal four-helix bundle domain of PLIN2 and the inner phospholipid leaflet of the apical plasma membrane lead to bilayer alterations that induce membrane curvature. Recruitment of the BTN1A1-XOR complex to CLD-membrane interaction sites stabilizes CLD-membrane interactions facilitating CLD membrane envelopment. PLIN2, red U-shaped structures surrounding CLD; BTN1A1, green modified oval structures; XOR, blue triangle structures.